Rapid improvement of pyoderma gangrenosum after treatment with infliximab

Joanna L. Chan, Michael S. Graves, Clay J. Cockerell, Amit G. Pandya

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Infliximab, a novel chimeric anti-tumor necrosis factor-α (TNF-α) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.

Original languageEnglish (US)
Pages (from-to)702-704
Number of pages3
JournalJournal of Drugs in Dermatology
Volume9
Issue number6
StatePublished - Jun 2010

Fingerprint

Pyoderma Gangrenosum
Psoriasis
Inflammatory Bowel Diseases
Appointments and Schedules
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Therapeutics
Infliximab

ASJC Scopus subject areas

  • Dermatology

Cite this

Chan, J. L., Graves, M. S., Cockerell, C. J., & Pandya, A. G. (2010). Rapid improvement of pyoderma gangrenosum after treatment with infliximab. Journal of Drugs in Dermatology, 9(6), 702-704.

Rapid improvement of pyoderma gangrenosum after treatment with infliximab. / Chan, Joanna L.; Graves, Michael S.; Cockerell, Clay J.; Pandya, Amit G.

In: Journal of Drugs in Dermatology, Vol. 9, No. 6, 06.2010, p. 702-704.

Research output: Contribution to journalArticle

Chan, JL, Graves, MS, Cockerell, CJ & Pandya, AG 2010, 'Rapid improvement of pyoderma gangrenosum after treatment with infliximab', Journal of Drugs in Dermatology, vol. 9, no. 6, pp. 702-704.
Chan JL, Graves MS, Cockerell CJ, Pandya AG. Rapid improvement of pyoderma gangrenosum after treatment with infliximab. Journal of Drugs in Dermatology. 2010 Jun;9(6):702-704.
Chan, Joanna L. ; Graves, Michael S. ; Cockerell, Clay J. ; Pandya, Amit G. / Rapid improvement of pyoderma gangrenosum after treatment with infliximab. In: Journal of Drugs in Dermatology. 2010 ; Vol. 9, No. 6. pp. 702-704.
@article{c5e03fcb6d3942d39e3cc85fcb080f6a,
title = "Rapid improvement of pyoderma gangrenosum after treatment with infliximab",
abstract = "Infliximab, a novel chimeric anti-tumor necrosis factor-α (TNF-α) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.",
author = "Chan, {Joanna L.} and Graves, {Michael S.} and Cockerell, {Clay J.} and Pandya, {Amit G.}",
year = "2010",
month = "6",
language = "English (US)",
volume = "9",
pages = "702--704",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "6",

}

TY - JOUR

T1 - Rapid improvement of pyoderma gangrenosum after treatment with infliximab

AU - Chan, Joanna L.

AU - Graves, Michael S.

AU - Cockerell, Clay J.

AU - Pandya, Amit G.

PY - 2010/6

Y1 - 2010/6

N2 - Infliximab, a novel chimeric anti-tumor necrosis factor-α (TNF-α) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.

AB - Infliximab, a novel chimeric anti-tumor necrosis factor-α (TNF-α) monoclonal antibody, has been increasingly used in the treatment of pyoderma gangrenosum. However, an established dosing regimen is lacking in the published literature. A variety of dosing regimens have been suggested, including a treatment schedule similar to that of psoriasis. The authors report a case of rapid response to infliximab in a patient with pyoderma gangrenosum associated with inflammatory bowel disease utilizing a dosing regimen similar to that used for psoriasis.

UR - http://www.scopus.com/inward/record.url?scp=77955865788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955865788&partnerID=8YFLogxK

M3 - Article

C2 - 20645536

AN - SCOPUS:77955865788

VL - 9

SP - 702

EP - 704

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 6

ER -